This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
This study examined the cost-effectiveness of antihypertensive therapy plus statin therapy, for patients aged 40 to 79 years, who had hypertension and a total cholesterol level of 6.5mmol/L or less, and it considered their adherence to treatment.
Interventions
Three scenarios were considered: no treatment, real-world adherence to treatment, and ideal adherence to treatment. Treatment was an antihypertensive regimen plus a statin, which was 10mg atorvastatin daily. Two antihypertensive regimens were considered amlodipine followed by perindopril and doxazosin, or atenolol followed by bendroflumethiazide and doxazosin.
Location/setting
USA/primary care.
Methods

Analytical approach:
The economic evaluation was based on a Markov model that assessed the costs and benefits of primary and secondary prevention, using antihypertensive and statin therapy, for three scenarios, which were no treatment, ideal adherence (based on a clinical trial), and real-world adherence (based on Medicaid data). A lifetime horizon was considered and the authors stated that the analysis was carried out from the perspective of the payer.
The issue of uncertainty was investigated and the findings were generally robust. A clear description of the decision model was provided. The authors stated that the cost-effectiveness of ideal adherence might have been underestimated as it was not possible to estimate the emergency costs due to stroke and these were higher with partial adherence. The model did not consider the cost of implementing a programme to increase adherence from partial to ideal. Some assumptions were needed to extrapolate the data to the long term, but these were varied in the sensitivity analyses.
Concluding remarks:
The methods were valid and the extensive analysis of uncertainty showed that the results were robust, which supports the authors' conclusions.
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